Celsius Holdings to Participate in Upcoming Investor Conferences

BOCA RATON, Fla.--(BUSINESS WIRE)-- Celsius Holdings, Inc. (Nasdaq: CELH) (“the Company”) today announced it will participate in the following investor conferences:

Goldman Sachs Global Staples Forum
Date: May 12, 2026
Fireside chat webcast: May 12, approximately 8 a.m. ET

Deutsche Bank Global Consumer Conference
Date: June 2, 2026
Fireside chat webcast: June 2, approximately 5:15 p.m. CEST / 11:15 a.m. ET

Jefferies Consumer Conference
Date: June 16-17, 2026

Live webcasts (where applicable) will be available in the Events & Presentations section of the Company’s investor relations website at: https://ir.celsiusholdingsinc.com/events-and-presentations/. As disclosed in our Annual Report on Form 10-K filed with the Securities & Exchange Commission (the “SEC”) on April 14, 2026, we use our website and webcasts as means of disclosing material information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Attendees are reminded to join the webcasts before the planned start time to ensure a good connection and to allow for time to complete the free registration. We intend to make replays of the webcast noted above available on our website for at least 30 days after the original conference date.

About Celsius Holdings, Inc.
Celsius Holdings, Inc. (Nasdaq: CELH) is a functional beverage company and the owner of energy drink brand CELSIUS®, health and wellness brand Alani Nu® and Rockstar Energy®. Born in fitness and pioneering the rapidly growing, better-for-you, functional beverage category, the company creates and markets leading functional beverage products. For more information, please visit www.celsiusholdingsinc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260508832085/en/

Investor Relations Contact:
Paul Wiseman
[email protected]

Source: Celsius Holdings, Inc.

You May Also Be Interested In

• Definium Therapeutics plans $500M public share offering
• RedHill Biopharma closes $6M private placement with warrant upside
• Lilly's $7.8 billion acquisition of Centessa cleared by English court